Want to see JP:4549 full AI Analyst Report?
4549 Stock Chart & Stats
¥2580.00
-¥78.00(-3.07%)
At close: 4:00 PM EDT
¥2580.00
-¥78.00(-3.07%)
Day’s Range― - ―
52-Week Range¥2,151.00 - ¥3,500.00
Previous CloseN/A
Volume357.70K
Average Volume (3M)72.32K
Market Cap
¥70.91B
Enterprise Value¥79.97K
Total Cash (Recent Filing)¥10.94B
Total Debt (Recent Filing)¥7.29B
Price to Earnings (P/E)19.9
Beta0.66
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.7%
Share Statistics
EPS (TTM)112.51
Shares Outstanding34,541,440
10 Day Avg. Volume81,940
30 Day Avg. Volume72,320
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)2.29
Price to Sales (P/S)2.40
P/FCF Ratio-58.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.9
Revenue Forecast (FY)¥43.56B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables BusinessEiken's revenue is driven by recurring reagent and test-kit sales tied to test volume and installed analyzers. This consumables-heavy model creates predictable, repeatable demand and pull-through from installed bases, supporting durable revenue visibility and steady cash inflows over time.
Proprietary LAMP Molecular TechnologyOwnership of LAMP-based nucleic acid amplification gives Eiken a differentiated product technology in molecular diagnostics. This proprietary capability supports sustained product differentiation, licensing/partnership opportunities and repeat consumable sales tied to unique assays, helping long-term competitiveness.
Conservative Balance Sheet With Low LeverageLow leverage and a sizable equity cushion give Eiken financial flexibility to fund R&D, reagent/instrument placement, or weather cash-flow volatility. A modest rise in debt is noted, but the conservative capital structure supports durable stability and lowers refinancing risk over the medium term.
Bears Say
Negative Free Cash Flow In 2026Free cash flow turning negative signals a material deterioration in cash conversion versus prior years. This reduces internal funding for instruments, R&D, or dividends and may force reliance on external financing or slower reinvestment, constraining sustainable organic growth.
Significant Margin CompressionA durable decline in gross and operating margins points to structural pressures—pricing weakness, adverse mix, or rising costs. Compressed margins reduce earnings power and reinvestable cash, making it harder to finance growth or maintain returns even if revenue stabilizes.
Top-line Weakness And Slow RecoveryA pronounced 2024 revenue drop with only modest recovery implies lingering demand weakness or competitive share loss. Limited top-line growth restrains scalability of the consumables model and hampers margin recovery, making long-term earnings improvement more challenging.
Eiken Chemical Co., Ltd. News
4549 FAQ
What was Eiken Chemical Co., Ltd.’s price range in the past 12 months?
Eiken Chemical Co., Ltd. lowest stock price was ¥2151.00 and its highest was ¥3500.00 in the past 12 months.
What is Eiken Chemical Co., Ltd.’s market cap?
Eiken Chemical Co., Ltd.’s market cap is ¥70.91B.
When is Eiken Chemical Co., Ltd.’s upcoming earnings report date?
Eiken Chemical Co., Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 80 days.
How were Eiken Chemical Co., Ltd.’s earnings last quarter?
Eiken Chemical Co., Ltd. released its earnings results on Jul 30, 2026. The company reported ¥13.52 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Eiken Chemical Co., Ltd. overvalued?
According to Wall Street analysts Eiken Chemical Co., Ltd.’s price is currently Overvalued.
Does Eiken Chemical Co., Ltd. pay dividends?
Eiken Chemical Co., Ltd. pays a Semiannually dividend of ¥29 which represents an annual dividend yield of 2.7%. See more information on Eiken Chemical Co., Ltd. dividends here
What is Eiken Chemical Co., Ltd.’s EPS estimate?
Eiken Chemical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eiken Chemical Co., Ltd. have?
Eiken Chemical Co., Ltd. has 34,541,440 shares outstanding.
What happened to Eiken Chemical Co., Ltd.’s price movement after its last earnings report?
Eiken Chemical Co., Ltd. reported an EPS of ¥13.52 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.159%.
Which hedge fund is a major shareholder of Eiken Chemical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4549
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eiken Chemical Co., Ltd.
Eiken Chemical Co., Ltd. is a Japanese manufacturer and distributor specializing in clinical diagnostic products and medical equipment. The company excels in developing diagnostic solutions for diverse medical fields, encompassing biochemical analysis, immunology, serology, dry chemical assays, and automated diagnostic systems. A significant offering is the OC-SENSOR, an automated immunochemical fecal test designed to identify gastrointestinal bleeding linked to conditions such as colorectal cancer, polyps, and diverticulitis. Its comprehensive product portfolio further includes real-time turbidimeters, temperature-controlled equipment, various amplification and fluorescence detection reagents for research applications, and general detection kits. Eiken Chemical also produces a variety of microbiology-related products, alongside additional immunological and serological reagents. Established in Tokyo, Japan, in 1939, the company initially operated as Nihon Eiyokagaku Co., Ltd. until its rebranding to Eiken Chemical Co., Ltd. in 1969.
Technical Analysis
PHC Holdings Corp.
―
Techno Medica Co., Ltd.
―
Rion Co., Ltd.
―
Nihon Kohden Corporation
―